Lilly’s lupus treatment succeeds in mid-stage trial

(Reuters) – Eli Lilly & Co said on Wednesday its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year.

FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 18, 2018. REUTERS/Brendan McDermid

The data come two weeks after U.S. health regulators approved the drug, baricitinib, under the trade name Olumiant, with a far more restrictive label than expected to treat rheumatoid arthritis.

There are few…

Read More Here

Be the first to comment on "Lilly’s lupus treatment succeeds in mid-stage trial"

Leave a comment

Your email address will not be published.